Clinical Trial Update: Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating short-term pre-operative durvalumab (MEDI-4736) in patients with early-stage small triple-negative breast cancer (cT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Early Small (cT1N0) Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING